Treatment Satisfaction with and Adherence to Disease-Modifying Antirheumatic Drugs in Adult Patients with Juvenile Idiopathic Arthritis.
To examine medication satisfaction and adherence and their relationships to disease variables and health-related quality of life (HRQOL) in adults with juvenile idiopathic arthritis (JIA). Patients (N=96, mean age 25 years, 67% female) completed questionnaires about their health-status 19 years after disease onset. Patients using biological disease-modifying antirheumatic drugs (bDMARDs) or methotrexate were assessed with the Morisky Medication Adherence Scale (MMAS-8) and the Treatment Satisfaction Questionnaire for Medication (TSQM), including dimensions of effectiveness, side effects, convenience and global satisfaction. DMARDs were used by 52 patients (54%) (mean age 25 years, 75% female), of which 28 used methotrexate and 37 used bDMARDs. Patients using combination therapy of methotrexate and bDMARDs (n=15) reported higher satisfaction with bDMARDs than methotrexate in the dimensions of side effects and global satisfaction (mean 92.9±15.5 vs 56.2±30.9 and 67.6±19.8 vs 47.1±21.7, p<0.001 and p=0.016, respectively). Patients using either bDMARDs (n=22) or methotrexate (n=13) reported higher satisfaction with bDMARDs than methotrexate for the dimensions of effectiveness and global satisfaction (mean 78.7±15.4 vs 60.2±19.9 and 73.6±17.7 vs 52.3±23.9, p=0.004 and p=0.005, respectively). Nearly half (46%) of patients reported low adherence (MMAS-8 score <6) and 25% high adherence (score =8). Higher levels of pain, psychological distress, more active joints and current MTX use were the strongest correlates of lower medication satisfaction. Perceived medication effectiveness and global satisfaction correlated positively with physical and mental HRQOL. JIA patients were more satisfied with bDMARDs than MTX, and 46% reported low adherence. Higher medication satisfaction was associated with better HRQOL.